Cargando…

Clusterin inhibition using OGX-011 synergistically enhances zoledronic acid activity in osteosarcoma

PURPOSE: Despite recent improvements in therapeutic management of osteosarcoma, ongoing challenges in improving the response to chemotherapy warrants new strategies still needed to improve overall patient survival. Among new therapeutic approaches, zoledronic acid (ZOL) represents a promising adjuva...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lamoureux, Francois, Baud'huin, Marc, Ory, Benjamin, Guiho, Romain, Zoubeidi, Amina, Gleave, Martin, Heymann, Dominique, Rédini, Françoise
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2014
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4202162/ https://www.ncbi.nlm.nih.gov/pubmed/25138053

Ejemplares similares

Clusterin inhibition using OGX-011 synergistically enhances antitumour activity of sorafenib in a human renal cell carcinoma model
por: Kususda, Y, et al.
Publicado: (2012)

Molecular Alterations Associated with Osteosarcoma Development
por: Ando, Kosei, et al.
Publicado: (2012)

Mechanisms of Resistance to Conventional Therapies for Osteosarcoma
por: Marchandet, Louise, et al.
Publicado: (2021)

Origin and Therapies of Osteosarcoma
por: Moukengue, Brice, et al.
Publicado: (2022)

Molecular Chaperones in Osteosarcoma: Diagnosis and Therapeutic Issues
por: Lallier, Morgane, et al.
Publicado: (2021)

Targeting the epigenetic readers in Ewing Sarcoma inhibits the oncogenic transcription factor EWS/Fli1
por: Jacques, Camille, et al.
Publicado: (2016)

miRNA-193a-5p repression of p73 controls Cisplatin chemoresistance in primary bone tumors
por: Jacques, Camille, et al.
Publicado: (2016)

Farnesyl diphosphate synthase is involved in the resistance to zoledronic acid of osteosarcoma cells
por: Ory, B, et al.
Publicado: (2008)

Ewing sarcoma from molecular biology to the clinic
por: Dupuy, Maryne, et al.
Publicado: (2023)

Loss of miR-198 and -206 during primary tumor progression enables metastatic dissemination in human osteosarcoma
por: Georges, Steven, et al.
Publicado: (2018)

Ribosomopathies: New Therapeutic Perspectives
por: Orgebin, Emilien, et al.
Publicado: (2020)

Implication of the p53-Related miR-34c, -125b, and -203 in the Osteoblastic Differentiation and the Malignant Transformation of Bone Sarcomas
por: Jacques, Camille, et al.
Publicado: (2020)

TH1579, MTH1 inhibitor, delays tumour growth and inhibits metastases development in osteosarcoma model
por: Moukengue, Brice, et al.
Publicado: (2020)

OGX-427 inhibits tumor progression and enhances gemcitabine chemotherapy in pancreatic cancer
por: Baylot, V, et al.
Publicado: (2011)

Zoledronic acid inhibits pulmonary metastasis dissemination in a preclinical model of Ewing’s sarcoma via inhibition of cell migration
por: Odri, Guillaume, et al.
Publicado: (2014)

Clusterin facilitates stress-induced lipidation of LC3 and autophagosome biogenesis to enhance cancer cell survival
por: Zhang, Fan, et al.
Publicado: (2014)

The p53 Family Members p63 and p73 Roles in the Metastatic Dissemination: Interactions with microRNAs and TGFβ Pathway
por: Rodriguez Calleja, Lidia, et al.
Publicado: (2022)

Current Therapeutic Strategies and Novel Approaches in Osteosarcoma
por: Ando, Kosei, et al.
Publicado: (2013)

Imatinib Mesylate Exerts Anti-Proliferative Effects on Osteosarcoma Cells and Inhibits the Tumour Growth in Immunocompetent Murine Models
por: Gobin, Bérengère, et al.
Publicado: (2014)

Tracking Targets of Dynamic Super-Enhancers in Vitro to Better Characterize Osteoclastogenesis and to Evaluate the Effect of Diuron on the Maturation of Human Bone Cells
por: Tesfaye, Robel A., et al.
Publicado: (2023)

A combination of methotrexate and zoledronic acid prevents bone erosions and systemic bone mass loss in collagen induced arthritis
por: Le Goff, Benoit, et al.
Publicado: (2009)

(99m)Tc-NTP 15-5 assessment of the early therapeutic response of chondrosarcoma to zoledronic acid in the Swarm rat orthotopic model
por: Miot-Noirault, Elisabeth, et al.
Publicado: (2013)

Jaw osteosarcoma models in mice: first description
por: Bertin, Hélios, et al.
Publicado: (2019)

Sostdc1: A soluble BMP and Wnt antagonist that is induced by the interaction between myeloma cells and osteoblast lineage cells
por: Faraahi, Z., et al.
Publicado: (2019)

Corrigendum to “Sostdc1: A soluble BMP and Wnt antagonist that is induced by the interaction between myeloma cells and osteoblast lineage cells” [Bone 122 (May 2019) 82–92]
por: Faraahi, Z., et al.
Publicado: (2019)

Co‐targeting driver pathways in prostate cancer: two birds with one stone
por: Zoubeidi, Amina, et al.
Publicado: (2018)

Anticancer activity of halofuginone in a preclinical model of osteosarcoma: inhibition of tumor growth and lung metastases
por: Lamora, Audrey, et al.
Publicado: (2015)

Safety Concern between Autologous Fat Graft, Mesenchymal Stem Cell and Osteosarcoma Recurrence
por: Perrot, Pierre, et al.
Publicado: (2010)

Interaction of Cutibacterium ( formerly Propionibacterium) acnes with bone cells: a step toward understanding bone and joint infection development
por: Aubin, Guillaume Ghislain, et al.
Publicado: (2017)

Tumour Heterogeneity: The Key Advantages of Single-Cell Analysis
por: Tellez-Gabriel, Marta, et al.
Publicado: (2016)

Overexpression of the Ubiquitin Specific Proteases USP43, USP41, USP27x and USP6 in Osteosarcoma Cell Lines: Inhibition of Osteosarcoma Tumor Growth and Lung Metastasis Development by the USP Antagonist PR619
por: Lavaud, Mélanie, et al.
Publicado: (2021)

Bone Tumor Environment as a Potential Therapeutic Target in Ewing Sarcoma
por: Redini, Françoise, et al.
Publicado: (2015)

OA011-03. Clusterin, a natural ligand of DC-SIGN present in human semen inhibits HIV capture and transmission by dendritic cells
por: Sabatte, J, et al.
Publicado: (2009)

Zoledronic acid is an effective radiosensitizer in the treatment of osteosarcoma
por: Kim, Eun Ho, et al.
Publicado: (2016)

TRAIL-Based Therapies Efficacy in Pediatric Bone Tumors Models Is Modulated by TRAIL Non-Apoptotic Pathway Activation via RIPK1 Recruitment
por: Brion, Régis, et al.
Publicado: (2022)

Transforming Growth Factor-β Signaling Plays a Pivotal Role in the Interplay Between Osteosarcoma Cells and Their Microenvironment
por: Verrecchia, Franck, et al.
Publicado: (2018)

LIM Kinases in Osteosarcoma Development
por: Brion, Régis, et al.
Publicado: (2021)

Preliminary Results of the “Capasquelet” Technique for Managing Femoral Bone Defects—Combining a Masquelet Induced Membrane and Capanna Vascularized Fibula with an Allograft
por: Combal, Alexis, et al.
Publicado: (2021)

Osteoprotegerin inhibits bone resorption and prevents tumor development in a xenogenic model of Ewing's sarcoma by inhibiting RANKL
por: Picarda, Gaëlle, et al.
Publicado: (2013)

The Osteosarcoma Microenvironment: A Complex but Targetable Ecosystem
por: Corre, Isabelle, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_bm0as9737n4kg3iin7o7gmgpab